Abionic SA
10
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
20.0%
2 terminated/withdrawn out of 10 trials
80.0%
-6.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Evaluation of Immunoassay Measurements of Pancreatic Stone Protein Performed on abioSCOPE® Device With the PSP Assay on ICU Patients at Risk of Sepsis as an Aid in Identifying Sepsis
Role: lead
abioSCOPE PSP Reference Range Study; Extension of AB-PSP-003
Role: lead
Prospective Study to Validate the Diagnostic Performance of IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2
Role: lead
Analytical Validation of the abioSCOPE Device With the IVD CAPSULE PSP Test: Comparison of PSP Values Measured With Venous Whole Blood and Those Measured With Arterial Whole Blood.
Role: lead
Analytical Validation of the abioSCOPE Device With a PSP Test: Point-of-Care Precision, Sample Type Comparison and Sample Stability
Role: collaborator
Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population
Role: lead
abioSCOPE IgE Assay to Aid in the Diagnosis of Allergies
Role: lead
Analytical Validation of the abioSCOPE Device With an IgE Test Panel: Point-of-Care Precision, Sample Type Comparison and Method Correlation
Role: lead
Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.
Role: lead
Evaluation and Validation of Novel Diagnostic Tool for Allergists (AbioSCOPE)
Role: collaborator
All 10 trials loaded